A Phase 3 Study of MEDI-524 (Numax) for the Prevention of RSV Disease Among Native American Indian Infants in the Southwestern United States

Trial Profile

A Phase 3 Study of MEDI-524 (Numax) for the Prevention of RSV Disease Among Native American Indian Infants in the Southwestern United States

Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2011

At a glance

  • Drugs Motavizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 May 2011 Status changed from recruiting to completed.
    • 14 May 2008 Results are presented at the Pediatric Academic Societies (PAS) Annual Meeting.
    • 27 Dec 2007 Status changed from in progress to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top